Wednesday, June 10, 2026
🇺🇸 FDA

P1 · Therapeutic area intelligence

Oncology patent intelligence

Anticancer agents, immuno-oncology, ADC, and oncology patent filings — grants, expirations, and assignee activity.

Patents
2,004

Quick answer

2,004 US pharmaceutical patents in our index match Oncology title keywords (A61K/A61P). Cross-link to related drug therapeutic-area hubs and company patent portfolios for full IP context.

  1. US 7629380

    Antitumor agents

    The Regents of the University of California · Granted Tue Dec 08 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 03 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  2. US 7625563

    Cancer treatment methods using selected immunoconjugates for binding to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Tue Dec 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 26 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  3. US 7622105

    Modified cytokines for use in cancer therapy

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  4. US 7622556

    Modified cytokines for use in cancer therapy

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  5. US 7622118

    Cancer treatment methods using selected antibodies to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Tue Nov 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  6. US 7618936

    Methods for treating and diagnosing cancer with WNT inhibitory Factor-1 (WIF-1)

    The Regents of the University of California · Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  7. US 7619000

    S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(dimethylarsino) glutathione as treatments for cancer

    The Board of Regents of the University of Texas System · Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  8. US 7619057

    MHC class II restricted T cell epitopes from the cancer antigen, NY ESO-1

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Nov 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Nov 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  9. US 7612044

    Melanoma antigens and their use in diagnostic and therapeutic methods

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Nov 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  10. US 7595431

    Mouse models of human prostate cancer

    The Regents of the University of California · Granted Tue Sep 29 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 24 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  11. US 7582623

    Photoactive metal nitrosyls for blood pressure regulation and cancer therapy

    The Regents of the University of California · Granted Tue Sep 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  12. US 7582736

    Prostate cancer specific internalizing human antibodies

    The Regents of the University of California · Granted Tue Sep 01 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 27 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  13. US 7572891

    Kidney-specific tumor vaccine directed against kidney tumor antigen G-250

    The Regents of the University of California · Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  14. US 7572887

    Gene expressed in prostate cancer, methods and use thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  15. US 7572448

    Combined cancer treatment methods using selected antibodies to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Tue Aug 11 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Aug 06 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  16. US 7569673

    Humanized anti-tag 72 cc49 for diagnosis and therapy of human tumors

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Aug 04 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  17. US 7563446

    Methods and compositions for inducing autoimmunity in the treatment of cancers

    The Board of Regents of the University of Texas System · Granted Tue Jul 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  18. US 7560263

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue Jul 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  19. US 7560265

    Compositions for regulation of tumor necrosis factor-alpha

    The Regents of the University of Colorado, a Body Corporate · Granted Tue Jul 14 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 09 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  20. US 7556942

    Tumor suppressor designated Hippo

    The Board of Regents of the University of Texas System · Granted Tue Jul 07 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jul 02 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  21. US 7550141

    Methods for imaging tumor vasculature using conjugates that bind to aminophospholipids

    The Board of Regents of the University of Texas System · Granted Tue Jun 23 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 18 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  22. US 7547759

    Induction of tumor immunity by variants of folate binding protein

    The Board of Regents of the University of Texas System · Granted Tue Jun 16 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jun 11 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  23. US 7541034

    Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  24. US 7541035

    Immunogenic peptides for the treatment of prostate and breast cancer

    The United States of America as Represented by the Secretary of the Department of Health and Human Services · Granted Tue Jun 02 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 28 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  25. US 7537923

    Compositions of prokaryotic phenylalanine ammonia-lyase and methods of treating cancer using compositions thereof

    BIOMARIN PHARMACEUTICAL INC. · Granted Tue May 26 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 21 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  26. US 7534565

    DLC-1 gene deleted in cancers

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue May 19 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon May 14 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  27. US 7527786

    Methods for inhibiting the growth of cancer cells expressing PSCA

    The Regents of the University of California · Granted Tue May 05 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 30 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  28. US 7521414

    Polyol macrolide antitumor-antibiotics from the marine actinomycete strain CNQ140

    The Regents of the University of California · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  29. US 7521475

    Chondropsin-class antitumor V-ATPase inhibitor compounds, compositions and methods of use thereof

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Apr 21 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Apr 16 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  30. US 7504430

    Maleiimide anti-tumor phosphatase inhibitors

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  31. US 7501501

    MHC-Class II restricted melanoma antigens and their use in therapeutic methods

    The United States of America, as represented by the Secretary, Department of Health and Human Services · Granted Tue Mar 10 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Mar 05 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  32. US 7494775

    Compositions, kits, and methods for identification, assessment, prevention and therapy of breast and ovarian cancer

    UT Board of Regents · Granted Tue Feb 24 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 19 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  33. US 7491802

    Anti-BAMBI antibody and diagnostic or remedy for colon cancer and liver cancer

    Takeda Pharmaceutical Company Limited · Granted Tue Feb 17 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Feb 12 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  34. US 7485296

    PSCA: prostate stem cell antigen and uses thereof in pancreatic cancer

    The Regents of the University of California · Granted Tue Feb 03 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 29 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  35. US 7482002

    Method of administering and using VEGF inhibitors for the treatment of prostate cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 27 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 22 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  36. US 7479272

    Method of administering and using VEGF inhibitors for the treatment of breast cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  37. US 7479273

    Method of administering and using VEGF inhibitors for the treatment of renal cell cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  38. US 7479275

    Method of administering and using VEGF inhibitors for the treatment of colorectal cancer

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  39. US 7479483

    Tumor-targeted drug delivery systems and uses thereof

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  40. US 7479274

    Method of administering and using VEGF inhibitors for the treatment of pancreatic carcinoma

    REGENERON PHARMACEUTICALS, INC. · Granted Tue Jan 20 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 15 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  41. US 7476721

    Modified cytokines for use in cancer therapy

    FONDAZIONE CENTRO SAN RAFFAELE DEL MONTE TABOR · Granted Tue Jan 13 2009 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Jan 08 2029 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  42. US 7470431

    Use of neurotoxin therapy for treatment of urological-neurological disorders associated with prostate cancer

    The Regents of the University of Colorado · Granted Tue Dec 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  43. US 7468432

    Cobalamin conjugates useful as antitumor agents

    Regents of the University of Minnesota · Granted Tue Dec 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Dec 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  44. US 7442543

    Mammalian selenoprotein differentially expressed in tumor cells

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Oct 28 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 23 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  45. US 7432349

    Tumor suppressor gene, p28ING5

    The United States of America, as represented by the Department of Health and Human Services · Granted Tue Oct 07 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Oct 02 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  46. US 7429616

    Synthesis and complete stereochemical assignment of psymberin/irciniastatin for use as antitumor compounds

    The Board of Regents of the University of Texas System · Granted Tue Sep 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  47. US 7429457

    Id-1 and Id-2 genes and products as markers of epithelial cancer

    The Regents of the University of California · Granted Tue Sep 30 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 25 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

  48. US 7427496

    Anti-cancer compounds

    The Regents of the University of Colorado · Granted Tue Sep 23 2008 00:00:00 GMT+0000 (Coordinated Universal Time) · Expires Mon Sep 18 2028 00:00:00 GMT+0000 (Coordinated Universal Time)

    granted

Frequently asked questions

How many Oncology patents are indexed?

2,004 patents match our Oncology classifier (title keywords in USPTO records).

Is this legal or medical advice?

No — patent intelligence is for professional reference. Verify expiration and FTO with qualified patent counsel and primary USPTO records.

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.